JP2019519252A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019519252A5 JP2019519252A5 JP2019520507A JP2019520507A JP2019519252A5 JP 2019519252 A5 JP2019519252 A5 JP 2019519252A5 JP 2019520507 A JP2019520507 A JP 2019520507A JP 2019520507 A JP2019520507 A JP 2019520507A JP 2019519252 A5 JP2019519252 A5 JP 2019519252A5
- Authority
- JP
- Japan
- Prior art keywords
- adenovirus vector
- adenovirus
- vector according
- virus
- infection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000701161 unidentified adenovirus Species 0.000 claims 25
- 239000013598 vector Substances 0.000 claims 22
- 239000000427 antigen Substances 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 5
- 230000002163 immunogen Effects 0.000 claims 5
- 239000002773 nucleotide Substances 0.000 claims 5
- 125000003729 nucleotide group Chemical group 0.000 claims 5
- 108091026890 Coding region Proteins 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 210000004436 artificial bacterial chromosome Anatomy 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 241001465754 Metazoa Species 0.000 claims 3
- 230000028993 immune response Effects 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 3
- 244000052769 pathogen Species 0.000 claims 3
- 230000001717 pathogenic effect Effects 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 241000186359 Mycobacterium Species 0.000 claims 2
- 241000711798 Rabies lyssavirus Species 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 230000003308 immunostimulating effect Effects 0.000 claims 2
- 238000004806 packaging method and process Methods 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 201000008827 tuberculosis Diseases 0.000 claims 2
- 239000013603 viral vector Substances 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000010370 Adenoviridae Infections Diseases 0.000 claims 1
- 206010060931 Adenovirus infection Diseases 0.000 claims 1
- 108090000565 Capsid Proteins Proteins 0.000 claims 1
- 102100023321 Ceruloplasmin Human genes 0.000 claims 1
- 208000004293 Chikungunya Fever Diseases 0.000 claims 1
- 206010067256 Chikungunya virus infection Diseases 0.000 claims 1
- 201000003075 Crimean-Congo hemorrhagic fever Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 241000701022 Cytomegalovirus Species 0.000 claims 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 claims 1
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 claims 1
- 101710145505 Fiber protein Proteins 0.000 claims 1
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 claims 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 claims 1
- 241000711549 Hepacivirus C Species 0.000 claims 1
- 101710094396 Hexon protein Proteins 0.000 claims 1
- 241000701806 Human papillomavirus Species 0.000 claims 1
- 206010023927 Lassa fever Diseases 0.000 claims 1
- 241000222722 Leishmania <genus> Species 0.000 claims 1
- 208000004554 Leishmaniasis Diseases 0.000 claims 1
- 241000712079 Measles morbillivirus Species 0.000 claims 1
- 208000025370 Middle East respiratory syndrome Diseases 0.000 claims 1
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 claims 1
- 208000005647 Mumps Diseases 0.000 claims 1
- 206010062207 Mycobacterial infection Diseases 0.000 claims 1
- 241000186367 Mycobacterium avium Species 0.000 claims 1
- 241000588650 Neisseria meningitidis Species 0.000 claims 1
- 208000016045 Nipah virus disease Diseases 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 208000009608 Papillomavirus Infections Diseases 0.000 claims 1
- 208000026681 Paratuberculosis Diseases 0.000 claims 1
- 101710173835 Penton protein Proteins 0.000 claims 1
- 241000224016 Plasmodium Species 0.000 claims 1
- 206010037742 Rabies Diseases 0.000 claims 1
- 101900083372 Rabies virus Glycoprotein Proteins 0.000 claims 1
- 102000018120 Recombinases Human genes 0.000 claims 1
- 108010091086 Recombinases Proteins 0.000 claims 1
- 208000000705 Rift Valley Fever Diseases 0.000 claims 1
- 241000315672 SARS coronavirus Species 0.000 claims 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 claims 1
- 241000194017 Streptococcus Species 0.000 claims 1
- 108700019146 Transgenes Proteins 0.000 claims 1
- 208000001455 Zika Virus Infection Diseases 0.000 claims 1
- 241000907316 Zika virus Species 0.000 claims 1
- 208000035332 Zika virus disease Diseases 0.000 claims 1
- 208000020329 Zika virus infectious disease Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 208000011589 adenoviridae infectious disease Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 208000010710 hepatitis C virus infection Diseases 0.000 claims 1
- 208000021145 human papilloma virus infection Diseases 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 230000005847 immunogenicity Effects 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 108091070501 miRNA Proteins 0.000 claims 1
- 239000002679 microRNA Substances 0.000 claims 1
- 208000010805 mumps infectious disease Diseases 0.000 claims 1
- 208000027531 mycobacterial infectious disease Diseases 0.000 claims 1
- 244000045947 parasite Species 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 201000005404 rubella Diseases 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 241000712461 unidentified influenza virus Species 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022129264A JP7333857B2 (ja) | 2016-06-23 | 2022-08-15 | アデノウイルスベクター |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1610967.0A GB2549809C (en) | 2016-06-23 | 2016-06-23 | Vector |
| GB1610967.0 | 2016-06-23 | ||
| PCT/GB2017/051851 WO2017221031A1 (en) | 2016-06-23 | 2017-06-23 | Adenoviral vector |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022129264A Division JP7333857B2 (ja) | 2016-06-23 | 2022-08-15 | アデノウイルスベクター |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019519252A JP2019519252A (ja) | 2019-07-11 |
| JP2019519252A5 true JP2019519252A5 (https=) | 2020-08-06 |
| JP7187451B2 JP7187451B2 (ja) | 2022-12-12 |
Family
ID=56891578
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019520507A Active JP7187451B2 (ja) | 2016-06-23 | 2017-06-23 | アデノウイルスベクター |
| JP2022129264A Active JP7333857B2 (ja) | 2016-06-23 | 2022-08-15 | アデノウイルスベクター |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022129264A Active JP7333857B2 (ja) | 2016-06-23 | 2022-08-15 | アデノウイルスベクター |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11306325B2 (https=) |
| EP (2) | EP3475433B9 (https=) |
| JP (2) | JP7187451B2 (https=) |
| KR (1) | KR102205908B1 (https=) |
| CN (2) | CN109790548B (https=) |
| AU (1) | AU2017282102B2 (https=) |
| CA (1) | CA3027686A1 (https=) |
| DK (1) | DK3475433T3 (https=) |
| ES (1) | ES2883354T3 (https=) |
| GB (1) | GB2549809C (https=) |
| MX (1) | MX2018016074A (https=) |
| SG (1) | SG11201811178UA (https=) |
| WO (1) | WO2017221031A1 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201507393TA (en) | 2013-03-14 | 2015-10-29 | Salk Inst For Biological Studi | Oncolytic adenovirus compositions |
| KR102608590B1 (ko) | 2014-09-24 | 2023-12-01 | 솔크 인스티튜트 포 바이올로지칼 스터디즈 | 종양 살상 바이러스 및 이의 사용방법 |
| WO2017147269A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics |
| WO2017147265A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
| GB2549809C (en) | 2016-06-23 | 2022-11-30 | Univ Oxford Innovation Ltd | Vector |
| EP3532082A4 (en) | 2016-12-12 | 2020-08-26 | Salk Institute for Biological Studies | SYNTHETIC ADENOVIRUS TUMOR TARGETING AND THEIR USES |
| EP3634449A4 (en) | 2017-05-08 | 2021-03-17 | Gritstone Oncology, Inc. | ALPHAVIRUS NEOANTIGEN VECTORS |
| CN112292449A (zh) * | 2018-04-09 | 2021-01-29 | 萨克生物研究学院 | 具有增强的复制特性的溶瘤腺病毒组合物 |
| GB201812647D0 (en) | 2018-08-03 | 2018-09-19 | Chancellor Masters And Scholars Of The Univ Of Oxford | Viral vectors and methods for the prevention or treatment of cancer |
| GB201814141D0 (en) * | 2018-08-30 | 2018-10-17 | Univ Oxford Innovation Ltd | Method and compositions for producing a virus |
| GB201818084D0 (en) * | 2018-11-06 | 2018-12-19 | Univ Oxford Innovation Ltd | Compositions and methods |
| CN109602901B (zh) * | 2019-01-08 | 2022-05-27 | 成都迈科康生物科技有限公司 | 一种带状疱疹病毒疫苗及其制备方法和应用 |
| MX2021014525A (es) * | 2019-05-30 | 2022-03-17 | Gritstone Bio Inc | Adenovirus modificados. |
| DK4037708T3 (da) | 2019-09-30 | 2024-09-30 | Gilead Sciences Inc | HBV-vacciner og fremgangsmåder til at behandle HBV |
| CN113088530A (zh) * | 2020-01-08 | 2021-07-09 | 怡道生物科技(苏州)有限公司 | 一种基于黑猩猩ChAd63型腺病毒的表达载体及其构建方法 |
| CN113088538A (zh) * | 2020-01-08 | 2021-07-09 | 怡道生物科技(苏州)有限公司 | 一种基于黑猩猩ChAd3型腺病毒的表达载体及其构建方法 |
| US12521429B2 (en) | 2020-02-05 | 2026-01-13 | New York Blood Center, Inc. | Zika virus immunogenic compositions |
| US12023376B1 (en) | 2020-04-17 | 2024-07-02 | Triad National Security, Llc | Conserved region T cell vaccines for coronavirus and methods of use |
| RU2720614C9 (ru) * | 2020-04-23 | 2021-02-09 | федеральное государственное бюджетное учреждение «Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи» Министерства здравоохранения Российской Федерации | Иммунобиологическое средство и способ его использования для индукции специфического иммунитета против вируса тяжелого острого респираторного синдрома SARS-CoV-2 (варианты) |
| JP7369276B2 (ja) * | 2020-08-22 | 2023-10-25 | フェデラル ステート バジェタリー インスティテューション“ナショナル リサーチ センター フォー エピデミオロジー アンド マイクロバイオロジー ネームド アフター ザ オナラリー アカデミシャン エヌ．エフ．ガマレヤ”オブ ザ ミニストリー オブ ヘルス オブ ザ ロシアン フェデレーション | 重症急性呼吸器症候群ウイルスｓａｒｓ－ｃｏｖ－２に対する発現ベクター |
| WO2022122036A1 (zh) * | 2020-12-10 | 2022-06-16 | 武汉博沃生物科技有限公司 | 一种SARS-CoV-2病毒的免疫原、药物组合物及其应用 |
| CN112552380B (zh) * | 2020-12-10 | 2021-12-24 | 武汉博沃生物科技有限公司 | 一种SARS-CoV-2病毒的免疫原及其应用 |
| CN112831524B (zh) * | 2021-02-20 | 2023-06-13 | 苏州相奕生物技术有限公司 | 人工改造的重组腺病毒载体、由其包装的病毒及其应用 |
| TW202323529A (zh) | 2021-10-18 | 2023-06-16 | 美商再生元醫藥公司 | 包括腺病毒相關病毒聚核苷酸的真核細胞 |
| CN116103242B (zh) * | 2023-01-10 | 2024-08-02 | 潍坊医学院 | 一种靶向治疗结核病的esat6-car-t细胞及其制备方法和应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602005017743D1 (de) * | 2004-01-23 | 2009-12-31 | Angeletti P Ist Richerche Bio | Impfstoffträger für schimpansen-adenovirus |
| PL2391638T3 (pl) * | 2009-02-02 | 2018-11-30 | Glaxosmithkline Biologicals Sa | Sekwencje nukleotydowe i aminokwasowe małpiego adenowirusa, zawierające je wektory i ich zastosowania |
| GB201108879D0 (en) * | 2011-05-25 | 2011-07-06 | Isis Innovation | Vector |
| CN103987726B (zh) * | 2011-10-05 | 2017-10-03 | 金维克有限公司 | 猴(大猩猩)腺病毒或腺病毒载体及其使用方法 |
| GB201318084D0 (en) * | 2013-10-11 | 2013-11-27 | Isis Innovation | Malaria vaccination |
| WO2015063647A1 (en) * | 2013-11-01 | 2015-05-07 | Pfizer Inc. | Vectors for expression of prostate-associated antigens |
| GB201413530D0 (en) * | 2014-07-30 | 2014-09-10 | Isis Innovation | Treatment and prevention of malaria |
| GB2549809C (en) | 2016-06-23 | 2022-11-30 | Univ Oxford Innovation Ltd | Vector |
-
2016
- 2016-06-23 GB GB1610967.0A patent/GB2549809C/en active Active
-
2017
- 2017-06-23 EP EP17734440.5A patent/EP3475433B9/en active Active
- 2017-06-23 AU AU2017282102A patent/AU2017282102B2/en active Active
- 2017-06-23 SG SG11201811178UA patent/SG11201811178UA/en unknown
- 2017-06-23 JP JP2019520507A patent/JP7187451B2/ja active Active
- 2017-06-23 WO PCT/GB2017/051851 patent/WO2017221031A1/en not_active Ceased
- 2017-06-23 DK DK17734440.5T patent/DK3475433T3/da active
- 2017-06-23 ES ES17734440T patent/ES2883354T3/es active Active
- 2017-06-23 US US16/310,281 patent/US11306325B2/en active Active
- 2017-06-23 MX MX2018016074A patent/MX2018016074A/es unknown
- 2017-06-23 CN CN201780039028.8A patent/CN109790548B/zh active Active
- 2017-06-23 CA CA3027686A patent/CA3027686A1/en active Pending
- 2017-06-23 CN CN202410243409.XA patent/CN118460616A/zh active Pending
- 2017-06-23 KR KR1020197002318A patent/KR102205908B1/ko active Active
- 2017-06-23 EP EP21182840.5A patent/EP3943604A1/en active Pending
-
2022
- 2022-01-28 US US17/587,376 patent/US11970709B2/en active Active
- 2022-08-15 JP JP2022129264A patent/JP7333857B2/ja active Active
-
2024
- 2024-04-02 US US18/624,929 patent/US12365920B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019519252A5 (https=) | ||
| Tatsis et al. | Adenoviruses as vaccine vectors | |
| Gherardi et al. | Recombinant poxviruses as mucosal vaccine vectors | |
| Hanke et al. | Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime | |
| JP2018536433A5 (https=) | ||
| JP2021182922A5 (https=) | ||
| US8389275B2 (en) | Fusion proteins of HIV regulatory/accessory proteins | |
| JP2014516536A5 (https=) | ||
| RU2013152648A (ru) | Аденовирус обезьян и гибридные аденовирусные векторы | |
| Otten et al. | Enhanced potency of plasmid DNA microparticle human immunodeficiency virus vaccines in rhesus macaques by using a priming-boosting regimen with recombinant proteins | |
| JP6153473B2 (ja) | Ｂ型肝炎ウイルスコアタンパク質をコードする核酸分子およびそれを含むワクチン | |
| FI3371316T3 (fi) | Rokotteita hepatiitti b -virusta vastaan | |
| JP2013501038A5 (https=) | ||
| Grimm et al. | Vaccine design: emerging concepts and renewed optimism | |
| JP2001514000A5 (https=) | ||
| JP2002542827A5 (https=) | ||
| JP2017515508A5 (https=) | ||
| EA003554B1 (ru) | Фармацевтическая композиция для генерации противовирусного иммунного ответа у человека и животного | |
| JP2004501646A5 (https=) | ||
| JP2010538649A5 (https=) | ||
| JP2008514203A5 (https=) | ||
| JP2022078067A5 (https=) | ||
| Schoenly et al. | Human immunodeficiency virus type 1 vaccine development: recent advances in the cytotoxic T-lymphocyte platform “spotty business” | |
| WO2009141434A4 (en) | Expression vector encoding alphavirus replicase and the use thereof as immunological adjuvant | |
| US20060073123A1 (en) | Adenovirus vectors for immunotherapy |